| Literature DB >> 16080074 |
E Mondou1, J Sorbel, J Anderson, H Mommeja-Marin, A Rigney, F Rousseau.
Abstract
Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine occurred in 23% of patients. Development of antibody to hepatitis e antigen did not prevent hepatic flare. One patient with marked bridging fibrosis required liver transplantation. Patients with advanced liver disease are at risk for hepatic flare with decompensation if active treatment is withdrawn (e.g., when highly active antiretroviral treatment is modified).Entities:
Mesh：
Substances：
Year: 2005 PMID： 16080074 DOI： 10.1086/432581
Source DB: PubMed Journal: Clin Infect Dis ISSN： 1058-4838 Impact factor: 9.079